Intranasal ciclesonide for allergic rhinitis

Review

(3567) Views  (922) Full article downloads

Authors: Ben Williams, William B Smith, Frank E Kette

Published Date November 2008 Volume 2008:1 Pages 49 - 54

DOI: http://dx.doi.org/10.2147/JAA.S3082

Ben Williams, William B Smith, Frank E Kette

Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, South Australia

Abstract: Ciclesonide is a novel corticosteroid which is optimized for topical use. It is a pro-drug which is activated locally in the airway mucosa, lipid-conjugated for local retention, and has very high protein binding in circulation leading to low systemic bioavailability. These characteristics should lead to highly selective activity with reduced local and systemic side effects. It has been established as an inhaled medication for asthma and has also been shown in double-blind trials to be efficacious for the treatment of seasonal and perennial allergic rhinitis. However no data have yet demonstrated superiority over existing nasal topical corticosteroids, either in terms of efficacy or adverse effects, and trials have not yet clearly shown efficacy in rhinitis in children. Therefore the place of ciclesonide in the treatment of allergic rhinitis relative to other existing products remains unclear.

Keywords: nasal corticosteroid efficacy, ciclesonide, allergic rhinitis